All In MedTech

Device Trial Radar · NCT07927413

Effectiveness and Safety of TachoSil® Fibrin Sealant Patch for Supporting Dural Sealing Among Adult Inpatients

Effectiveness and Safety of TachoSil® Fibrin Sealant Patch in Comparison to a Hydrogel Sealant for Supporting Dural Sealing Among Adult Inpatients in the United States: A Retrospective, Non-Inferiority, Cohort Study

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Nov 16, 2026

Study completion Nov 16, 2026

Sponsor

Lead sponsor
Corza Medical GmbHNot on our public-company list
Sponsor type
Industry
Collaborators
Comprehensive Information and Analytics Services (CIAS); Premier, Inc. Applied Sciences
First posted
Nov 10, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This retrospective observational cohort study compares the effectiveness and safety of adjunctive TachoSil® fibrin sealant patch with DuraSeal® hydrogel sealant for supporting dural sealing in adult patients undergoing cranial or spinal surgery at participating United States hospitals. Medical records will be reviewed to assess clinically evident cerebrospinal fluid leak or clinically evident pseudomeningocele within 90 days after surgery. The study will use 1:1 propensity score matching to evaluate whether TachoSil® is non-inferior to DuraSeal® and will assess additional effectiveness and safety outcomes.

Conditions

  • Cerebrospinal Fluid (CSF) Leak
  • Psuedomeningocele

Interventions

  • TachoSil®Drug

    TachoSil® is an absorbable fibrin sealant patch consisting of equine collagen coated with human fibrinogen and thrombin.

  • DuraSeal®Device

    DuraSeal® sealants are polyethylene glycol (PEG) based hydrogel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Risk of Clinically Evident CSF Leak or Clinically Evident PseudomeningoceleTime frame: Within 90 days post surgery

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio · Recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.